Par Drugs and Chemicals share news, announcements and annual reports
NSE: PARPharmaceuticals & BiotechnologySmall Cap
Par Drugs and Chemicals Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2019 · Issue price ₹124
Last close ₹114.96up ₹5.47 (5.00%)
Share price at the NSE close on 28 Oct 2026. Previous close ₹109.49.
28 Oct: open ₹109.49, high ₹114.96, low ₹105.01
52-week range of traded prices to 28 Oct 2026
₹78.05Low, 30 Mar 2026₹180.00High, 3 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Next results date: the board meets on 29 Oct 2026 to consider: financial results and other business matters. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹141 Cr2,825th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 9.76
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.26
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 13.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 14.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 8,997
Par Drugs and Chemicals disputes and clarifications
12 filed, newest first.
Jun 2026
10 Jun · Legal
May 2026
21 May · Legal
Mar 2026
26 Mar · Legal
Dec 2025
13 Dec · Legal
Oct 2025
27 Oct · Legal
Sep 2025
16 Sep · Legal
Jun 2025
19 Jun · Legal
12 Jun · Legal
Jul 2022
6 Jul · Legal
The exchange asked on 6 Jul 2022
Sep 2021
30 Sep · Legal
The exchange asked on 29 Sep 2021
Jun 2021
14 Jun · Legal
Exchange has sought clarification from Par Drugs And Chemicals Limited with respect to announcement dated 10-Jun-2021, regarding starting a new product line facility. On basis of above the Company is required to clarify following: 1. Name of the product;2. Date of launch;3. Category of the product;4. Whether caters to domestic/ international market;5. Name of the countries in which the product is launched (in case of international).The response of the Company is awaited.